NKGen Biotech, Inc. (NASDAQ:NKGNW) Short Interest Down 89.7% in December

NKGen Biotech, Inc. (NASDAQ:NKGNW) saw a significant decline in short interest in December. As of December 15th, there was short interest totalling 1,700 shares, a decline of 89.7% from the November 30th total of 16,500 shares. Based on an average daily trading volume, of 12,800 shares, the short-interest ratio is currently 0.1 days.

NKGen Biotech Stock Performance

NASDAQ NKGNW remained flat at $0.10 on Friday. 28,091 shares of the company traded hands, compared to its average volume of 18,433. The company’s 50-day moving average price is $0.05 and its two-hundred day moving average price is $0.07. NKGen Biotech has a 12 month low of $0.02 and a 12 month high of $0.29.

About NKGen Biotech

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.